GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

OCUL · Mar 31, 2026

OCULAR THERAPEUTIX, INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001104659-26-055256General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

43.23% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-611.90% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

0.81% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

34.65% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

87.68% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-865.46% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

613.94% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

144.48% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 23.12%
Current: 43.23%
Delta: 20.11%

Cash Generation Decreased

Previous: -394.38%
Current: -611.90%
Delta: -217.52%

Growth Increased

Previous: -18.47%
Current: 0.81%
Delta: 19.29%

Inventory Pressure Increased

Previous: 6.86%
Current: 34.65%
Delta: 27.79%

Margin Increased

Previous: 87.35%
Current: 87.68%
Delta: 0.33%

Profitability Decreased

Previous: -519.75%
Current: -865.46%
Delta: -345.71%

R And D Intensity Increased

Previous: 379.39%
Current: 613.94%
Delta: 234.55%

Sbc Intensity Increased

Previous: 83.12%
Current: 144.48%
Delta: 61.35%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · OCUL Fundamental State →Transitioned To · OCUL CAPEX_INTENSITY_INCREASED →Transitioned To · OCUL CASH_GENERATION_DECREASED →Transitioned To · OCUL GROWTH_INCREASED →Transitioned To · OCUL INVENTORY_PRESSURE_INCREASED →Transitioned To · OCUL MARGIN_INCREASED →Transitioned To · OCUL PROFITABILITY_DECREASED →Transitioned To · OCUL R_AND_D_INTENSITY_INCREASED →Transitioned To · OCUL SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.